Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Drug-Induced Liver Injury from Statins

Meurer, Lindsay, Cohen, Stanley Martin · 2020 · Clinics in Liver Disease

Abstract

The hydroxymethyglutaryl-coenzyme A reductase inhibitors (statins) are a commonly prescribed class of medication for the treatment of hyperlipidemia and coronary artery disease. This class of medication has several proven benefits, including reduction of mortality related to coronary artery disease. A major consideration when prescribing these drugs are the potential for adverse effects, mainly myalgias, myopathy, and hepatotoxicity. In this article, we summarize current data on statin-associated hepatotoxicity and highlight that the risk of clinically significant idiosyncratic drug-induced liver injury is actually quite small. We also review preclinical data suggesting potential hepatoprotective effects of statin therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cld.2019.09.007

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 54

  1. Sirtori, 2014, The pharmacology of statins, Pharmacol Res, 88, 3, 10.1016/j.phrs.2014.03.002 · DOI · Paper page
  2. Guyton, 2014, An assessment by the Statin Intolerance Panel: 2014 update, J Clin Lipidol, 8, S72, 10.1016/j.jacl.2014.03.002 · DOI · Paper page
  3. Bełtowski, 2009, Adverse effects of statins - mechanisms and consequences, Curr Drug Saf, 4, 209, 10.2174/157488609789006949 · doi:10.2174/157488609789006949
  4. Ramkumar, 2016, Statin therapy: review of safety and potential side effects, Acta Cardiol Sin, 32, 631
  5. Russo, 2014, Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network, Hepatology, 60, 679, 10.1002/hep.27157 · DOI · Paper page
  6. Chalasani, 2005, Statins and hepatotoxicity: focus on patients with fatty liver, Hepatology, 41, 690, 10.1002/hep.20671 · DOI · Paper page
  7. de Denus, 2004, Statins and liver toxicity: a meta-analysis, Pharmacotherapy, 24, 584, 10.1592/phco.24.6.584.34738 · DOI · Paper page
  8. Newman, 2006, Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients, Am J Cardiol, 97, 61, 10.1016/j.amjcard.2005.07.108 · DOI · Paper page
  9. Alsheikh-Ali, 2007, Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials, J Am Coll Cardiol, 50, 409, 10.1016/j.jacc.2007.02.073 · DOI · Paper page
  10. Kasliwal, 2007, Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients, Drug Saf, 30, 157, 10.2165/00002018-200730020-00005 · DOI
  11. Sniderman, 2004, Is there value in liver function test and creatine phosphokinase monitoring with statin use?, Am J Cardiol, 94, 30F, 10.1016/j.amjcard.2004.07.052 · DOI
  12. Björnsson, 2005, Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 · DOI · Paper page
  13. Björnsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J Hepatol, 56, 374, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
  14. Perdices, 2014, Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry, Rev Esp Enferm Dig, 106, 246
  15. Medina-Caliz, 2016, Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J Hepatol, 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
  16. Temple, 2006, Hy’s law: predicting serious hepatotoxicity, Pharmacoepidemiol Drug Saf, 15, 241, 10.1002/pds.1211 · DOI · Paper page
  17. Russo, 2004, Liver transplantation for acute liver failure from drug induced liver injury in the United States, Liver Transpl, 10, 1018, 10.1002/lt.20204 · DOI · Paper page
  18. Haque, 2016, Drug-induced liver injury: pattern recognition and future directions, Gut Liver, 10, 27, 10.5009/gnl15114 · DOI
  19. Nakayama, 2011, Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin, Indian J Gastroenterol, 30, 97, 10.1007/s12664-011-0092-x · DOI
  20. Pelli, 2003, Autoimmune hepatitis revealed by atorvastatin, Eur J Gastroenterol Hepatol, 15, 921, 10.1097/00042737-200308000-00014 · DOI
  21. Cohen, 2006, An assessment of statin safety by hepatologists, Am J Cardiol, 97, 77C, 10.1016/j.amjcard.2005.12.014 · DOI · Paper page
  22. Bays, 2014, An assessment by the Statin Liver Safety Task Force: 2014 update, J Clin Lipidol, 8, S47, 10.1016/j.jacl.2014.02.011 · DOI · Paper page
  23. Liu, 2009, Bicyclol: a novel drug for treating chronic viral hepatitis B and C, Med Chem, 5, 29, 10.2174/157340609787049316 · DOI
  24. Liu, 2005, Mechanism of protective action of bicyclol against CCl4-induced liver injury in mice, Liver Int, 25, 872, 10.1111/j.1478-3231.2005.01103.x · DOI
  25. Naiqiong, 2017, A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury, Med Sci Monit, 23, 5760, 10.12659/MSM.904090 · DOI
  26. Mizrahi, 2018, Glycosphingolipids prevent APAP and HMG-CoA reductase inhibitors-mediated liver damage: a novel method for “safer drug” formulation that prevents drug-induced liver injury, J Clin Transl Hepatol, 6, 127
  27. Moctezuma-Velázquez, 2018, The use of statins in patients with chronic liver disease and cirrhosis, Curr Treat Options Gastroenterol, 16, 226, 10.1007/s11938-018-0180-4 · DOI
  28. Segarra-Newnham, 2007, Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus, Pharmacotherapy, 27, 845, 10.1592/phco.27.6.845 · DOI
  29. Vuppalanchi, 2006, Statins for hyperlipidemia in patients with chronic liver disease: are they safe?, Clin Gastroenterol Hepatol, 4, 838, 10.1016/j.cgh.2006.04.020 · DOI
  30. Khorashadi, 2006, Incidence of statin hepatotoxicity in patients with hepatitis C, Clin Gastroenterol Hepatol, 4, 902, 10.1016/j.cgh.2006.03.014 · DOI
  31. Avins, 2008, Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study, Drug Saf, 31, 325, 10.2165/00002018-200831040-00006 · DOI
  32. Chang, 2015, Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study, J Gastroenterol Hepatol, 30, 155, 10.1111/jgh.12657 · DOI
  33. Francque, 2016, Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications, J Hepatol, 65, 425, 10.1016/j.jhep.2016.04.005 · DOI · Paper page
  34. Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 128, 1287, 10.1053/j.gastro.2004.02.015 · DOI · Paper page
  35. Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study, Atherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008 · DOI · Paper page
  36. Ekstedt, 2007, Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study, J Hepatol, 47, 135, 10.1016/j.jhep.2007.02.013 · DOI · Paper page
  37. Eslami, 2013, Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, Cochrane Database Syst Rev
  38. Athyros, 2018, Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk, Curr Vasc Pharmacol, 16, 246, 10.2174/1570161115666170621082910 · DOI · Paper page
  39. Riley, 2009, Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk, Cardiovasc Ther, 27, 216, 10.1111/j.1755-5922.2009.00088.x · DOI
  40. Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases, Hepatology, 67, 328, 10.1002/hep.29367 · DOI · Paper page
  41. Vargas, 2017, Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects, Curr Gastroenterol Rep, 19, 43, 10.1007/s11894-017-0584-7 · DOI
  42. Imprialos, 2018, The potential role of statins in treating liver disease, Expert Rev Gastroenterol Hepatol, 12, 331, 10.1080/17474124.2018.1439379 · DOI
  43. Gracia-Sancho, 2011, Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver, Gut, 60, 517, 10.1136/gut.2010.220913 · DOI
  44. Marrone, 2013, The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins, J Hepatol, 58, 98, 10.1016/j.jhep.2012.08.026 · DOI · Paper page
  45. Marrone, 2015, KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins, Gut, 64, 1434, 10.1136/gutjnl-2014-308338 · DOI · Paper page
  46. Zafra, 2004, Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis, Gastroenterology, 126, 749, 10.1053/j.gastro.2003.12.007 · DOI · Paper page
  47. El-Ashmawy, 2015, Antifibrotic effect of AT-1 blocker and statin in rats with hepatic fibrosis, Clin Exp Pharmacol Physiol, 42, 979, 10.1111/1440-1681.12446 · DOI
  48. Arab, 2016, Statins and portal hypertension: a tale of two models, Hepatology, 63, 2044, 10.1002/hep.28567 · DOI
  49. Abraldes, 2009, Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial, Gastroenterology, 136, 1651, 10.1053/j.gastro.2009.01.043 · DOI · Paper page
  50. Alexandropoulos, 2017, Protective effects of N-acetylcysteine and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion, Biomed Pharmacother, 89, 673, 10.1016/j.biopha.2017.02.086 · DOI
  51. Cámara-Lemarroy, 2014, Hepatic ischemia/reperfusion injury is diminished by atorvastatin in Wistar rats, Arch Med Res, 45, 210, 10.1016/j.arcmed.2014.02.001 · DOI
  52. Kocak, 2015, Protective effects of simvastatin administered in the experimental hepatic ischemia-reperfusion injury rat model, J Surg Res, 199, 393, 10.1016/j.jss.2015.06.009 · DOI
  53. Bader, 2008, Fluvastatin inhibits hepatitis C replication in humans, Am J Gastroenterol, 103, 1383, 10.1111/j.1572-0241.2008.01876.x · DOI · Paper page
  54. Huang, 2016, Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study, Am J Gastroenterol, 111, 976, 10.1038/ajg.2016.179 · DOI

Cited by

See all 39

Metadata

Authors
Meurer, L., & Cohen, S. M.
Venue
Clinics in Liver Disease
Publisher
Elsevier BV
Published
2020-02
Volume
24
Issue
1
Pages
107-119
ISSN
1089-3261
Cited by
39
References
2
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.